BioCentury
ARTICLE | Clinical News

Roche reports Phase II dry AMD data

August 27, 2013 11:55 PM UTC

Roche (SIX:ROG; OTCQX:RHHBY) said monthly lampalizumab ( RG7417) met the primary endpoint of reducing geographic atrophy (GA) area from baseline to month 18 vs. sham injection in the single-blind Phase II MAHALO trial to treat GA, an advanced form of dry age-related macular degeneration (AMD). Lampalizumab given every other month missed the primary endpoint. Data were presented at the American Society of Retina Specialists meeting in Toronto. Roche said it is still determining next steps for lampalizumab. ...